Repair & Recovery Stack: BPC-157, TB-500 and KPV

How Repair & Recovery Stack works

BPC-157 and TB-500 are studied for tissue repair signaling, blood vessel growth and cell migration. KPV is a three-amino-acid fragment (lysine-proline-valine) from the tail of alpha-melanocyte-stimulating hormone. In cell and mouse studies it entered gut cells through a transporter called PepT1 and dampened inflammatory signaling such as NF-kB. The rationale is that calming inflammation could support repair, but this has not been shown in humans.

Who it’s for, and who it isn’t

What’s included

• Online assessment and visit with a licensed clinician
• Review of injury, gut history, cancer history, medications and sport participation
• Prescription only if appropriate and if a licensed pharmacy can lawfully dispense it
• Medication shipped from a licensed U.S. compounding pharmacy
• Follow-up to review progress and decide whether to continue
• No membership fee (labs priced separately)

Possible side effects

• Injection-site redness, itching, bruising or swelling
• Possible immune reactions; FDA has noted gaps in safety information for these peptides
• Side effects of the three-peptide combination have not been studied
• Long-term effects in people are unknown

This isn’t a complete list. Your clinician reviews risks, interactions and warnings with you before prescribing. In an emergency, call 911.

What the evidence says

BPC-157 evidence is almost all animal research, with one uncontrolled human case series. TB-500 is a fragment of thymosin beta-4, whose full-length form has had early human trials, but the fragment has not. KPV's key studies are in human cell lines and mice with induced colitis. No clinical trial has tested any two of these together, let alone all three.

Three peptides, three different ideas

BPC-157 is a 15-amino-acid synthetic peptide modeled on a gastric protein fragment. Animal studies suggest it influences blood vessel growth and tissue repair in tendons, muscle and the gut lining.

TB-500 is a short lab-made fragment related to thymosin beta-4, a protein that helps cells move toward an injury.

KPV is the smallest of the three: just lysine, proline and valine, the last three amino acids of alpha-melanocyte-stimulating hormone. It is studied for its anti-inflammatory effects rather than for repair directly.

What KPV adds, according to the research

A 2008 study in Gastroenterology found that KPV is carried into intestinal cells by a transporter called PepT1, which becomes more active in inflamed colon tissue. In human cell cultures, small amounts of KPV reduced inflammatory signaling. In mice with chemically induced colitis, KPV in drinking water reduced inflammation.

Those findings are interesting, especially for gut inflammation. But they come from cells and mice, and KPV has not been shown to treat inflammatory bowel disease or support injury recovery in people. The FDA's own entry for KPV states that the agency lacks important information about its safety.

How this differs from the Wolverine Stack

The Wolverine Stack contains BPC-157 and TB-500. This stack adds KPV for people whose recovery picture includes an inflammatory element, as judged by a clinician.

More ingredients do not mean more benefit. Each added peptide adds its own unknowns, and a reaction becomes harder to trace. Your clinician may recommend the simpler option, a single peptide, or no peptide at all.

Regulatory status as of October 2026

None of the three peptides is FDA-approved. All three were previously listed in Category 2 of the FDA's interim lists of bulk substances for compounding. In April 2026 their nominations were withdrawn, and the FDA moved them to its nominated-but-withdrawn list. That was not a safety finding and did not place them in Category 1.

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, on each of BPC-157, KPV and TB-500, recommending them for the 503A bulks list. KPV's proposed uses were wound healing and inflammatory conditions. The votes are advisory; the FDA must still finish notice-and-comment rulemaking, which had not happened as of October 2026.

We only arrange a prescription when a licensed pharmacy confirms it can lawfully dispense the product under current federal and state rules.

Safety screening before anything is prescribed

Your clinician reviews your injury, any gut symptoms, your medications and your cancer history. Thymosin beta-4 has raised concern in laboratory research about supporting tumor growth, so active cancer is a firm stop.

Gut symptoms such as blood in the stool, unexplained weight loss or a lasting change in bowel habits need a medical work-up, not a peptide. If you compete in tested sport, note that BPC-157 and thymosin beta-4 fragments are prohibited under the WADA list.

What follow-up looks like

Before you start, your clinician agrees with you on what you are trying to change, such as pain with a specific movement, training volume you can tolerate, or a gut symptom already evaluated by a doctor. Writing that down makes it possible to judge the stack honestly later.

At follow-up, you review that goal, any side effects and whether anything else changed, such as rehab, sleep or training. Many recovery problems improve with time alone, so a clear before-and-after picture matters. If there is no meaningful change, or any reaction worries you, stopping is a reasonable and common decision.

Compounded, not FDA-approved, and priced plainly

This stack is a compounded preparation made by a licensed U.S. pharmacy for one patient. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. Dosing is set by your clinician, and we do not publish home dosing protocols.

The price is from $300/month, or $550 for two months ($275/month), with no membership fee, confirmed during your eligibility review. Labs are priced separately.

Go deeper on Repair & Recovery Stack